Open-source antibodies as a path to enhanced research reproducibility and transparency
Antibodies are important tools with diverse uses in biomedical research. However, open access to reliable sources of well-characterized antibodies with unambiguous molecular identities remains an obstacle to research transparency and reproducibility. We propose here a community shift towards open-source antibodies, analogous to open-source computer software. The tenets of such antibodies are that 1) they are available to researchers in a ready to use form, 2) the renewable source of the antibody (e.g., hybridoma cells or plasmid) is also widely available ensuring reproducible and cost-effective access to the same antibody, and 3) the antibody sequence is publicly available. With these criteria met, the antibody can be widely used with the transparent assurance associated with a molecularly defined reagent, and the code can be edited to generate antibody variants to meet researchers' specific needs. We (the UC Davis/NIH NeuroMab Facility, the Development Studies Hybridoma Bank, and Addgene) have established a consortium to provide open-source access to a large collection of well characterized antibodies. As open-source software has benefitted both users and developers, we suggest open-source antibodies will have a similar positive impact on antibody based biomedical research. We encourage funding agencies to support initiatives to expand access to open-source antibody resources, and researchers to both utilize and to contribute to them, with a goal of enabling more reliable and cost-effective pursuit of research.
Authors
- Karl D. Murray (ORCID: https://orcid.org/0000-0001-8159-6843)
- Ming Fan (ORCID: https://orcid.org/0000-0001-8676-2716)
- James S. Trimmer
- Meghan A. Rego (ORCID: https://orcid.org/0000-0003-1991-2715)
- Douglas W. Houston (ORCID: https://orcid.org/0000-0002-7438-4655)
Institutions
- Developmental Studies Hybridoma Bank (US)
- NeuroMab (US)
- Addgene (US)
- University of California, Davis (US)
Publication Details
- Journal
- New Biotechnology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1016/j.nbt.2025.04.004
- Citations
- 5
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 6.80
Funders
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke